Search
01/08/2021
Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial
Rojas, J, de Lazzari, E, Negredo, E, Domingo, P, Tiraboschi, J, Ribera, E, Abdulghani, N, Puig, J, Mateo, MG, Podzamczer, D, Gutierrez, MM, Paredes, R, Clotet, B, Gatell, JM, Blanco, JL, Martinez, E, DOLAM Study Grp. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial. Lancet HIV. 2021; 8(8)DOI:10.1016/S2352-3018(21)00100-4. PMID:34358497. IF:16.070(Q1/1D).
01/08/2021
Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM)
Jimenez-Labaig, P, Pacheco-Barcia, V, Cebria, A, Galvez, F, Obispo, B, Paez, D, Quilez, A, Quintanar, T, Ramchandani, A, Remon, J, Rogado, J, Sanchez, DA, Sanchez-Canovas, M, Sanz-Garcia, E, Sesma, A, Tarazona, N, Cotes, A, Gonzalez, E, Bosch-Barrera, J, Fernandez, A, Felip, E, Vera, R, Rodriguez-Lescure, A, Elez, E. Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM). ESMO Open. 2021; 6(4)DOI:10.1016/j.esmoop.2021.100215. PMID:34325108. IF:6.883(Q1/3D).
01/08/2021
Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations
Wilson, BE, Desnoyers, A, Nadler, MB, Tibau, A, Amir, E. Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations. Cancer Medicine. 2021; 10(16)DOI:10.1002/cam4.4029. PMID:34323019. IF:4.711(Q2/5D).
01/08/2021
Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations
Martin, I, Villamon, E, Abellan, R, Calasanz, MJ, Irigoyen, A, Sanz, G, Such, E, Mora, E, Gutierrez, M, Collado, R, Garcia-Serra, R, Vara, M, Blanco, ML, Oiartzabal, I, Alvarez, S, Bernal, T, Granada, I, Xicoy, B, Jerez, A, Calabuig, M, Diez, R, Gil, A, Diez-Campelo, M, Solano, C, Tormo, M. Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations. BRITISH JOURNAL OF HAEMATOLOGY. 2021; 194(4)DOI:10.1111/bjh.17675. PMID:34296432. IF:8.615(Q1/2D).
01/08/2021
Rational engineering of a human GFP-like protein scaffold for humanized targeted nanomedicines
Alamo, P, Cedano, J, Conchillo-Sole, O, Cano-Garrido, O, Alba-Castellon, L, Serna, N, Avino, A, Carrasco-Diaz, LM, Sanchez-Chardi, A, Martinez-Torro, C, Gallardo, A, Cano, M, Eritja, R, Villaverde, A, Mangues, R, Vazquez, E, Unzueta, U. Rational engineering of a human GFP-like protein scaffold for humanized targeted nanomedicines. Acta Biomaterialia. 2021; 130DOI:10.1016/j.actbio.2021.06.001. PMID:34116228. IF:10.633(Q1/2D).
01/08/2021
Current Trends and Controversies in the Management of Warthin Tumor of the Parotid Gland
Quer, M, Hernandez-Prera, JC, Silver, CE, Casasayas, M, Simo, R, Vander Poorten, V, Guntinas-Lichius, O, Bradley, PJ, Tong-Ng, W, Rodrigo, JP, Makitie, AA, Rinaldo, A, Kowalski, LP, Sanabria, A, de Bree, R, Takes, RP, Lopez, F, Olsen, KD, Shaha, AR, Ferlito, A. Current Trends and Controversies in the Management of Warthin Tumor of the Parotid Gland. Diagnostics. 2021; 11(8)DOI:10.3390/diagnostics11081467. PMID:34441400. IF:3.992(Q2/4D).